A Phase I Study of PRT543 in People with Advanced Melanoma and Blood Cancers


Full Title

A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies


The purpose of this study is to find the highest dose of the investigational drug PRT543 that can be used safely in patients with metastatic melanoma or recurrent or persistent myelodysplastic syndromes (MDS) or myelofibrosis. PRT543 blocks PRMT5, a protein that can cause cancer cell growth. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic melanoma or recurrent or persistent MDS or myelofibrosis.
  • Patients should recover from the serious side effects of prior therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Eytan Stein at 646-608-3749.





Disease Status

Newly Diagnosed & Relapsed/Refractory